• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞适应在致癌过程中利用返祖退化程序。

Cellular Adaptation Takes Advantage of Atavistic Regression Programs during Carcinogenesis.

作者信息

Gnocchi Davide, Nikolic Dragana, Paparella Rosa Rita, Sabbà Carlo, Mazzocca Antonio

机构信息

Interdisciplinary Department of Medicine, University of Bari School of Medicine, Piazza G. Cesare, 11, 70124 Bari, Italy.

出版信息

Cancers (Basel). 2023 Aug 3;15(15):3942. doi: 10.3390/cancers15153942.

DOI:10.3390/cancers15153942
PMID:37568758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10416974/
Abstract

Adaptation of cancer cells to extreme microenvironmental conditions (i.e., hypoxia, high acidity, and reduced nutrient availability) contributes to cancer resilience. Furthermore, neoplastic transformation can be envisioned as an extreme adaptive response to tissue damage or chronic injury. The recent Systemic-Evolutionary Theory of the Origin of Cancer (SETOC) hypothesizes that cancer cells "revert" to "primitive" characteristics either ontogenically (embryo-like) or phylogenetically (single-celled organisms). This regression may confer robustness and maintain the disordered state of the tissue, which is a hallmark of malignancy. Changes in cancer cell metabolism during adaptation may also be the consequence of altered microenvironmental conditions, often resulting in a shift toward lactic acid fermentation. However, the mechanisms underlying the robust adaptive capacity of cancer cells remain largely unknown. In recent years, cancer cells' metabolic flexibility has received increasing attention among researchers. Here, we focus on how changes in the microenvironment can affect cancer cell energy production and drug sensitivity. Indeed, changes in the cellular microenvironment may lead to a "shift" toward "atavistic" biologic features, such as the switch from oxidative phosphorylation (OXPHOS) to lactic acid fermentation, which can also sustain drug resistance. Finally, we point out new integrative metabolism-based pharmacological approaches and potential biomarkers for early detection.

摘要

癌细胞对极端微环境条件(即缺氧、高酸度和营养物质可用性降低)的适应有助于癌症的恢复力。此外,肿瘤转化可被设想为对组织损伤或慢性损伤的一种极端适应性反应。最近的癌症起源系统进化理论(SETOC)假设癌细胞在个体发育上(类似胚胎)或系统发育上(单细胞生物)“恢复”到“原始”特征。这种退化可能赋予组织稳健性并维持其无序状态,而这是恶性肿瘤的一个标志。适应过程中癌细胞代谢的变化也可能是微环境条件改变的结果,通常会导致向乳酸发酵的转变。然而,癌细胞强大的适应能力背后的机制在很大程度上仍然未知。近年来,癌细胞的代谢灵活性在研究人员中受到越来越多的关注。在这里,我们关注微环境的变化如何影响癌细胞的能量产生和药物敏感性。事实上,细胞微环境的变化可能导致向“返祖”生物学特征的“转变”,例如从氧化磷酸化(OXPHOS)转变为乳酸发酵,这也可以维持耐药性。最后,我们指出了基于代谢的新的综合药理学方法和早期检测的潜在生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87b4/10416974/0f9e6253ca4b/cancers-15-03942-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87b4/10416974/3923e426cf70/cancers-15-03942-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87b4/10416974/90534a47991c/cancers-15-03942-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87b4/10416974/0f9e6253ca4b/cancers-15-03942-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87b4/10416974/3923e426cf70/cancers-15-03942-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87b4/10416974/90534a47991c/cancers-15-03942-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87b4/10416974/0f9e6253ca4b/cancers-15-03942-g003.jpg

相似文献

1
Cellular Adaptation Takes Advantage of Atavistic Regression Programs during Carcinogenesis.细胞适应在致癌过程中利用返祖退化程序。
Cancers (Basel). 2023 Aug 3;15(15):3942. doi: 10.3390/cancers15153942.
2
Lactic acid fermentation: A maladaptive mechanism and an evolutionary throwback boosting cancer drug resistance.乳酸发酵:一种适应不良的机制和进化倒退,增强了癌症药物耐药性。
Biochimie. 2023 May;208:180-185. doi: 10.1016/j.biochi.2023.01.005. Epub 2023 Jan 11.
3
Mitochondrial biogenesis: pharmacological approaches.线粒体生物合成:药理学方法。
Curr Pharm Des. 2014;20(35):5507-9. doi: 10.2174/138161282035140911142118.
4
The Systemic-Evolutionary Theory of the Origin of Cancer (SETOC): A New Interpretative Model of Cancer as a Complex Biological System.癌症起源的系统-进化理论(SETOC):作为一个复杂生物系统的癌症的新解释模型。
Int J Mol Sci. 2019 Oct 2;20(19):4885. doi: 10.3390/ijms20194885.
5
Neoplastic growth: the consequence of evolutionary malignant resistance to chronic damage for survival of cells (review of a new theory of the origin of cancer).肿瘤生长:细胞为在慢性损伤中存活而产生的进化性恶性抗性的结果(癌症起源新理论综述)
Med Hypotheses. 2005;65(3):595-604. doi: 10.1016/j.mehy.2005.02.033.
6
The reproductive life cycle of cancer: Hypotheses of cell of origin, TP53 drivers and stem cell conversions in the light of the atavistic cancer cell theory.癌症的生殖生命周期:起源细胞假说、TP53 驱动因子和干细胞转化的假设,基于返祖癌细胞理论。
Med Hypotheses. 2019 Feb;123:19-23. doi: 10.1016/j.mehy.2018.12.006. Epub 2018 Dec 8.
7
Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).大分子拥挤现象:化学与物理邂逅生物学(瑞士阿斯科纳,2012年6月10日至14日)
Phys Biol. 2013 Aug;10(4):040301. doi: 10.1088/1478-3975/10/4/040301. Epub 2013 Aug 2.
8
Roles of autophagy and metabolism in pancreatic cancer cell adaptation to environmental challenges.自噬与代谢在胰腺癌细胞适应环境挑战中的作用。
Am J Physiol Gastrointest Liver Physiol. 2017 Nov 1;313(5):G524-G536. doi: 10.1152/ajpgi.00138.2017. Epub 2017 Jul 13.
9
Metabolic reprogramming: the emerging concept and associated therapeutic strategies.代谢重编程:新兴概念及相关治疗策略
J Exp Clin Cancer Res. 2015 Oct 6;34:111. doi: 10.1186/s13046-015-0221-y.
10
Is Cancer Metabolism an Atavism?癌症代谢是一种返祖现象吗?
Cancers (Basel). 2024 Jun 29;16(13):2415. doi: 10.3390/cancers16132415.

引用本文的文献

1
Metabolic reprogramming and functional crosstalk within the tumor microenvironment (TME) and A Multi-omics anticancer approach.肿瘤微环境(TME)中的代谢重编程与功能串扰以及多组学抗癌方法。
Med Oncol. 2025 Jul 24;42(9):373. doi: 10.1007/s12032-025-02945-5.
2
Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment.肿瘤中药物诱导的耐受性持久性细胞:机制、易损性及对临床治疗的潜在意义
Mol Cancer. 2025 May 24;24(1):150. doi: 10.1186/s12943-025-02323-9.
3
Portable multi-parametric microscopy for noninvasive metabolic and vascular imaging of orthotopic tongue cancer models .

本文引用的文献

1
Metabolism as a New Avenue for Hepatocellular Carcinoma Therapy.代谢作为肝细胞癌治疗的新途径。
Int J Mol Sci. 2023 Feb 13;24(4):3710. doi: 10.3390/ijms24043710.
2
Inhibition of lysophosphatidic acid receptor 6 upregulated by the choline-deficient l-amino acid-defined diet prevents hepatocarcinogenesis in mice.胆碱缺乏 L-氨基酸定义饮食上调的溶血磷脂酸受体 6 抑制可预防小鼠肝癌发生。
Mol Carcinog. 2023 May;62(5):577-582. doi: 10.1002/mc.23516. Epub 2023 Feb 8.
3
Lactic acid fermentation: A maladaptive mechanism and an evolutionary throwback boosting cancer drug resistance.
用于原位舌癌模型无创代谢和血管成像的便携式多参数显微镜
J Biomed Opt. 2025 Feb;30(Suppl 2):S23905. doi: 10.1117/1.JBO.30.S2.S23905. Epub 2025 Apr 23.
4
Traditional Chinese Medicine as a Tool for the Treatment of Hepatocellular Carcinoma by Targeting Pathophysiological Mechanism.以病理生理机制为靶点治疗肝细胞癌的中医药手段
Cancer Manag Res. 2025 Apr 8;17:779-792. doi: 10.2147/CMAR.S513729. eCollection 2025.
5
DLAT is involved in ovarian cancer progression by modulating lipid metabolism through the JAK2/STAT5A/SREBP1 signaling pathway.二氢硫辛酸转乙酰基酶(DLAT)通过JAK2/STAT5A/固醇调节元件结合蛋白1(SREBP1)信号通路调节脂质代谢,从而参与卵巢癌进展。
Cancer Cell Int. 2025 Jan 27;25(1):25. doi: 10.1186/s12935-025-03656-7.
6
The systemic evolutionary theory of the origin of cancer (SETOC): an update.癌症起源的系统进化理论(SETOC):最新进展
Mol Med. 2025 Jan 14;31(1):12. doi: 10.1186/s10020-025-01069-w.
7
The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations.去分化过程驱动的表观遗传改变中肺癌干细胞的分子特征。
J Biol Chem. 2024 Dec;300(12):107994. doi: 10.1016/j.jbc.2024.107994. Epub 2024 Nov 14.
8
Is Cancer Metabolism an Atavism?癌症代谢是一种返祖现象吗?
Cancers (Basel). 2024 Jun 29;16(13):2415. doi: 10.3390/cancers16132415.
9
Upregulation of EPSTI1/Drp1/AKT1 Signaling Pathways Using pDNA/Melittin Against Breast Cancer.利用质粒DNA/蜂毒肽上调EPSTI1/Drp1/AKT1信号通路以对抗乳腺癌
Biochem Genet. 2025 Jun;63(3):2276-2298. doi: 10.1007/s10528-024-10806-5. Epub 2024 May 9.
10
Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis.LPAR6 和 CAB39L 的缺失会扰乱基底到腔上皮的尿路上皮分化程序,导致膀胱癌的发生。
Cell Rep. 2024 May 28;43(5):114146. doi: 10.1016/j.celrep.2024.114146. Epub 2024 Apr 25.
乳酸发酵:一种适应不良的机制和进化倒退,增强了癌症药物耐药性。
Biochimie. 2023 May;208:180-185. doi: 10.1016/j.biochi.2023.01.005. Epub 2023 Jan 11.
4
Revisiting the Warburg Effect with Focus on Lactate.重新审视瓦伯格效应:聚焦乳酸
Cancers (Basel). 2022 Dec 7;14(24):6028. doi: 10.3390/cancers14246028.
5
Crithmum maritimum Improves Sorafenib Sensitivity by Decreasing Lactic Acid Fermentation and Inducing a Pro-Hepatocyte Marker Profile in Hepatocellular Carcinoma.滨海刺芹通过降低乳酸发酵并诱导肝癌细胞中促肝细胞标志物谱来提高索拉非尼敏感性。
Plant Foods Hum Nutr. 2023 Mar;78(1):230-232. doi: 10.1007/s11130-022-01037-3. Epub 2022 Dec 16.
6
What Are the Reasons for Continuing Failures in Cancer Therapy? Are Misleading/Inappropriate Preclinical Assays to Be Blamed? Might Some Modern Therapies Cause More Harm than Benefit?癌症治疗持续失败的原因是什么?是误导性/不适当的临床前检测方法应该受到指责吗?一些现代疗法会不会弊大于利?
Int J Mol Sci. 2022 Oct 30;23(21):13217. doi: 10.3390/ijms232113217.
7
Evolutionary View on Lactate-Dependent Mechanisms of Maintaining Cancer Cell Stemness and Reprimitivization.关于维持癌细胞干性和去分化的乳酸依赖性机制的进化观点
Cancers (Basel). 2022 Sep 20;14(19):4552. doi: 10.3390/cancers14194552.
8
A pro-oxidant combination of resveratrol and copper down-regulates hallmarks of cancer and immune checkpoints in patients with advanced oral cancer: Results of an exploratory study (RESCU 004).白藜芦醇与铜的促氧化组合可下调晚期口腔癌患者的癌症特征和免疫检查点:一项探索性研究(RESCU 004)的结果
Front Oncol. 2022 Sep 16;12:1000957. doi: 10.3389/fonc.2022.1000957. eCollection 2022.
9
Operation of a TCA cycle subnetwork in the mammalian nucleus.哺乳动物细胞核中三羧酸循环子网的运作。
Sci Adv. 2022 Sep 2;8(35):eabq5206. doi: 10.1126/sciadv.abq5206. Epub 2022 Aug 31.
10
Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma.抑制 LPAR6 通过将糖酵解切换为肝癌中的氧化磷酸化来克服索拉非尼耐药性。
Biochimie. 2022 Nov;202:180-189. doi: 10.1016/j.biochi.2022.07.016. Epub 2022 Aug 8.